Skip to Content

  • Search

View Additional Section Content

S1320 A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT02196181?term=NCT02196181&rank=1

Principal Investigator(s)
Willard G. Andrews III, MD

Clinical Trial Categories

  • Melanoma
Contact
The Rosenfeld Cancer Center at 215-481-2402

Location

  • The Rosenfeld Cancer Center

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM

Clinical Trials Details